Laquinimod, a new type of immumodulatory agent for relapsing-remitting multiple sclerosis, led to a 40% reduction in lesions, according to results of a multicenter, placebo-controlled phase IIb trial. Patients treated with laquinimod at a dose of 0.6 mg a day averaged 2.6 gadolinium-enhancing lesions on MRI compared with 4.2 for the placebo group (P=0.0048) as reported by Giancarlo Comi, M.D., of the University Vita-Salute and colleagues in the June issue of The Lancet.

The between-group difference emerged early in the trial, and follow-up beyond the primary study period demonstrated even larger reductions in MRI-detected lesions with laquinimod versus placebo. Additionally, the number of new lesions was reduced by 50% in the laquinimod group...............

For the full article please go to MSRC: MS Research News : Drugs : Laquinimod - http://www.msrc.co.uk/index.cfm?fuseaction=show&pageid=1735